Literature DB >> 9813388

Omeprazole for peptic ulcer disease in pregnancy.

G Brunner1, H Meyer, C Athmann.   

Abstract

This report contains the observations of 9 women who received omeprazole for severe reflux disease during different stages of pregnancy. Four patients took omeprazole at the time of conception, and 3 of these patients continued omeprazole therapy without interruption until delivery. One patient discontinued therapy in the 8th week of pregnancy but had to take the drug again from the 28th week to delivery. The other 5 patients started therapy in weeks 24, 30, 33, 34 and 36 of pregnancy because of bleeding in 2 patients and unbearable H2 receptor refractory reflux symptoms in the other 3 patients. All patients were carefully monitored. In all cases omeprazole was well tolerated. No severe side effects were observed in any of the mothers or their newborns. No malfunctions or malformations were observed in the newborns. Follow-up of the children between 2 and 12 years showed normal development in all children. These data together with the data on 8 such pregnancies published by other authors suggest that omeprazole is safe when given during pregnancy at whatever phase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813388     DOI: 10.1159/000007570

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

Review 1.  Risks versus benefits of gastrointestinal endoscopy during pregnancy.

Authors:  Mitchell S Cappell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-04       Impact factor: 46.802

Review 2.  Gastrointestinal endoscopy in pregnancy.

Authors:  Nurten Savas
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

3.  Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.

Authors:  G Brunner; C Athmann; J H Boldt
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

4.  Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.

Authors:  Shekoufeh Nikfar; Mohammad Abdollahi; Myla E Moretti; Laura A Magee; Gideon Koren
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

5.  Omeprazole stimulates the induction of human insulin-like growth factor binding protein-1 through aryl hydrocarbon receptor activation.

Authors:  Iain A Murray; Gary H Perdew
Journal:  J Pharmacol Exp Ther       Date:  2007-11-30       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.